A REVIEW ON CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY: A PARADIGM SHIFT IN CANCER IMMUNOTHERAPY

作者
Priyanka Gadi,Saniya Naaz,Lakshya Gayathri Reddy Karri,Dr. Tanwir Ahamad,Dr. Salamah Zaheer,Saravanagiri A,Adarsh. S. Kumar,Girish Adithya A,Dr.Vasudev Purushottam Pai,Dr.Varagani Srinivasa Rao
出处
期刊:Canadian journal of clinical pharmacology [Codon Publications]
标识
DOI:10.53555//xmj3t424
摘要

Chimeric Antigen Receptor (CAR) T-cell therapy has become one of the greatest breakthroughs in cancer immunotherapy, with the ability to cure patients with leukemias and lymphomas, thus changing the entire approach. The procedure made it possible to overcome the drawbacks of an ordinary T-cell response by turning it into an MHC-independent targeted, cytotoxicity with a patient’s T-cells that are genetically engineered to recognize and eliminate cancer-specific antigens. This review is about CAR-T cell therapy, describing its biological groundwork, the series of CAR constructs, the making process, action mechanism, and present-day FDA-approved clinical use, showing a vast range of information concerning CAR-T therapy. The investigation into the therapeutic advances in the treatment of leukemia, lymphoma, and multiple myeloma is illustrated along with the difficulties presented in the treatment of solid tumors, which are tumor heterogeneity, the problem of immunosuppressive microenvironments, antigen escape, and limited trafficking. The important toxicities of cytokine release syndrome and neurotoxicity are discussed with a major focus on grading, management strategies, and recent safety-improving developments. Innovations such as dual-target CARs, armored CAR-T cells, allogeneic “off-the-shelf” products, gene-edited CAR-T platforms, and the merging with checkpoint inhibitors point to the rapidly evolving future of this therapy. Finally, CAR-T cell therapy is a game changer in the oncology field, and if continued research expands its application to a greater number of tumors, it will be one of the most personalized, long-lasting, and powerful cancer treatment methods.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
小蘑菇的应助被Huangzhisong采纳,获得10
1秒前
2秒前
2秒前
2秒前
cdercder的应助被邦尼老师采纳,获得30
2秒前
淡人完成签到,获得积分10
3秒前
演九胜完成签到,获得积分10
3秒前
YeK1nDar发布了新的文献求助10
4秒前
动听的谷秋完成签到 ,获得积分10
4秒前
123发布了新的文献求助10
4秒前
4秒前
hermit发布了新的文献求助10
5秒前
5秒前
ccq的应助被阔达的冷霜采纳,获得10
5秒前
顾矜的应助被阔达的冷霜采纳,获得10
5秒前
传奇3的应助被阔达的冷霜采纳,获得10
5秒前
Hello的应助被阔达的冷霜采纳,获得10
5秒前
英俊的铭的应助被阔达的冷霜采纳,获得10
5秒前
6秒前
6秒前
7秒前
8秒前
华无剑的应助被多情的飞绿采纳,获得10
8秒前
一朵约尔发布了新的文献求助10
8秒前
Scarlett的应助被沉默的西装采纳,获得10
8秒前
10秒前
欣喜紫霜发布了新的文献求助10
11秒前
汉堡包的应助被鑫渊采纳,获得10
11秒前
yyy关闭了yyy的文献求助
11秒前
无辣不欢完成签到,获得积分10
11秒前
Lia完成签到,获得积分10
12秒前
13秒前
Ava的应助被果郭采纳,获得10
13秒前
一些小事完成签到,获得积分10
14秒前
Hang完成签到,获得积分10
15秒前
思源的应助被二马三乡采纳,获得10
16秒前
李爱国的应助被欣喜紫霜采纳,获得10
16秒前
hokubu完成签到,获得积分10
16秒前
Huangzhisong发布了新的文献求助10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177667
求助须知:如何正确求助?哪些是违规求助? 9568537
关于积分的说明 21799700
捐赠科研通 7772307
什么是DOI,文献DOI怎么找? 3432429
关于科研通互助平台的介绍 2556651
邀请新用户注册赠送积分活动 2478011